drugset / Trial / NCT00229437

Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy

NCT00229437

Phase 2 Completed 343 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the efficacy and safety of TAK-128, once daily (QD), in treating subjects with diabetic peripheral neuropathy.

Timeline

Start
2005-03
Primary completion
2006-05
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Sapanisertib Small molecule 5 mg Oral
Subject Sapanisertib Small molecule 50 mg Oral
Subject Sapanisertib Small molecule 100 mg Oral

Indications